Zevra Therapeutics, Inc. Stock Prediction and Forecast [ZVRA]
1 extracted signal · 1 resolved · 0 still active
StockInvest.usIndependent analyst profile- Source published
- 13 Aug 2025, 03:19 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
![Video preview for Zevra Therapeutics, Inc. Stock Prediction and Forecast [ZVRA]](https://i.ytimg.com/vi/Zv_EuCb7j_Y/hqdefault.jpg)
AI-generated source summary
The analysis suggests ZVRA is a buy candidate. The system has ranked Zevra Therapeutics as a buy candidate with a score of 3.492. Those who adhered to the analysis would have experienced a gain of approximately 50.96% since the initial recommendation 66 days prior, with an average daily gain of 0.77%. The stock is within a broad and strong upward trend, the current three month trend indicates a potential change of 43.34% over the upcoming three months with a possible return ranging from 32.66% to 72.75%. Analysts assign ZVRA a strong sell rating. Our stop loss is set at $11.29, 4% from current, with medium risk as we approach the third quarter, further regulatory developments may affect EMA approval, and favorable reimbursement dynamics are expected to be a key to upside, regulatory setbacks, or commercial hurdles, will constrain valuation.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
StockInvest.us
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.